Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR NASDAQ:KYTX NASDAQ:PGEN NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$5.47-4.2%$5.33$1.67▼$7.29$559.50M1.013.92 million shs4.93 million shsKYTXKyverna Therapeutics$3.63-2.4%$3.56$1.78▼$7.85$160.87M3.08288,527 shs225,702 shsPGENPrecigen$4.56-4.0%$2.42$0.65▼$5.22$1.42B1.8217.76 million shs6.05 million shsSIGASiga Technologies$8.49-1.4%$7.59$4.95▼$9.62$616.53M0.95626,638 shs545,080 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma-4.20%+2.24%+4.79%+1.67%+209.04%KYTXKyverna Therapeutics-2.42%-1.89%+6.45%+7.08%-51.28%PGENPrecigen-4.00%+0.22%+136.27%+204.00%+372.54%SIGASiga Technologies-1.39%+3.41%+28.64%+40.80%+8.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$5.47-4.2%$5.33$1.67▼$7.29$559.50M1.013.92 million shs4.93 million shsKYTXKyverna Therapeutics$3.63-2.4%$3.56$1.78▼$7.85$160.87M3.08288,527 shs225,702 shsPGENPrecigen$4.56-4.0%$2.42$0.65▼$5.22$1.42B1.8217.76 million shs6.05 million shsSIGASiga Technologies$8.49-1.4%$7.59$4.95▼$9.62$616.53M0.95626,638 shs545,080 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma-4.20%+2.24%+4.79%+1.67%+209.04%KYTXKyverna Therapeutics-2.42%-1.89%+6.45%+7.08%-51.28%PGENPrecigen-4.00%+0.22%+136.27%+204.00%+372.54%SIGASiga Technologies-1.39%+3.41%+28.64%+40.80%+8.15%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr Pharma$230K2,330.46N/AN/A$0.83 per share6.59KYTXKyverna Therapeutics$7.03M22.33N/AN/A$6.17 per share0.59PGENPrecigen$3.92M346.62N/AN/A$0.13 per share35.08SIGASiga Technologies$138.72M4.38$0.83 per share10.29$3.02 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)KYTXKyverna Therapeutics-$127.48M-$3.68N/AN/AN/AN/A-64.98%-56.17%11/12/2025 (Estimated)PGENPrecigen-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)SIGASiga Technologies$59.21M$1.137.516.79N/A45.73%40.52%35.62%11/6/2025 (Estimated)Latest KYTX, PGEN, SIGA, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025KYTXKyverna Therapeutics-$1.00-$0.97+$0.03-$0.97N/AN/A8/12/2025Q2 2025PGENPrecigen-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million8/7/2025Q2 2025ATYRaTyr Pharma-$0.18-$0.22-$0.04-$0.22N/AN/A8/5/2025Q2 2025SIGASiga TechnologiesN/A$0.49N/A$0.49N/A$81.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr Pharma0.015.635.63KYTXKyverna TherapeuticsN/A5.395.39PGENPrecigenN/A2.712.71SIGASiga TechnologiesN/A10.098.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%KYTXKyverna Therapeutics18.08%PGENPrecigen33.51%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipATYRaTyr Pharma3.70%KYTXKyverna Therapeutics22.00%PGENPrecigen47.10%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5397.99 million94.36 millionOptionableKYTXKyverna Therapeutics9643.25 million33.73 millionOptionablePGENPrecigen190297.97 million157.63 millionOptionableSIGASiga Technologies4071.61 million70.21 millionOptionableKYTX, PGEN, SIGA, and ATYR HeadlinesRecent News About These CompaniesTraders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)4 hours ago | marketbeat.comHealthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse...September 4 at 10:07 PM | marketbeat.comNuveen LLC Makes New $815,000 Investment in Siga Technologies Inc. $SIGASeptember 4 at 3:25 AM | marketbeat.comState of Wyoming Boosts Stake in Siga Technologies Inc. $SIGASeptember 2 at 5:44 AM | marketbeat.comWellington Management Group LLP Acquires 62,103 Shares of Siga Technologies Inc. $SIGASeptember 2 at 3:58 AM | marketbeat.comCharles Schwab Investment Management Inc. Cuts Stock Holdings in Siga Technologies Inc. $SIGASeptember 2 at 3:09 AM | marketbeat.comSiga Technologies Inc. $SIGA Shares Acquired by American Century Companies Inc.August 30, 2025 | marketbeat.comHotchkis & Wiley Capital Management LLC Increases Stock Position in Siga Technologies Inc. $SIGAAugust 26, 2025 | marketbeat.comSiga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)August 23, 2025 | marketbeat.comFirst Wilshire Securities Management Inc. Has $8.70 Million Stock Position in Siga Technologies Inc. $SIGAAugust 21, 2025 | marketbeat.comSIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA NewsAugust 20, 2025 | seekingalpha.comSiga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?August 15, 2025 | marketbeat.comWall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-BuyAugust 10, 2025 | marketbeat.comSIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)August 8, 2025 | finance.yahoo.comSiga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's WhyAugust 7, 2025 | marketbeat.comSIGA (SIGA) Q2 Revenue Soars 272%August 7, 2025 | theglobeandmail.comSiga Technologies (NASDAQ:SIGA) Issues Earnings ResultsAugust 6, 2025 | marketbeat.comSIGA Technologies (SIGA) Reports Significant Earnings DeclineAugust 6, 2025 | finance.yahoo.comSIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA fundingAugust 6, 2025 | msn.comSIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSIGA Reports Financial Results for Three and Six Months Ended June 30, 2025August 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYTX, PGEN, SIGA, and ATYR Company DescriptionsaTyr Pharma NASDAQ:ATYR$5.47 -0.24 (-4.20%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$5.48 +0.02 (+0.27%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Kyverna Therapeutics NASDAQ:KYTX$3.63 -0.09 (-2.42%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$3.63 +0.00 (+0.11%) As of 09/4/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Precigen NASDAQ:PGEN$4.56 -0.19 (-4.00%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$4.56 0.00 (0.00%) As of 04:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Siga Technologies NASDAQ:SIGA$8.49 -0.12 (-1.39%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$8.36 -0.14 (-1.59%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
